These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23402026)

  • 1. Defective complement action and control defines disease pathology for retinal and renal disorders and provides a basis for new therapeutic approaches.
    Zipfel PF; Lauer N
    Adv Exp Med Biol; 2013; 735():173-87. PubMed ID: 23402026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel roles of complement in renal diseases and their therapeutic consequences.
    Wada T; Nangaku M
    Kidney Int; 2013 Sep; 84(3):441-50. PubMed ID: 23615508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement biology for hematologists.
    Duval A; Frémeaux-Bacchi V
    Am J Hematol; 2023 May; 98 Suppl 4():S5-S19. PubMed ID: 36688486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling complement-driven diseases in transgenic mice: Values and limitations.
    Ueda Y; Gullipalli D; Song WC
    Immunobiology; 2016 Oct; 221(10):1080-90. PubMed ID: 27371974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of the complement system in age-related macular degeneration: a review.
    Troutbeck R; Al-Qureshi S; Guymer RH
    Clin Exp Ophthalmol; 2012; 40(1):18-26. PubMed ID: 22304025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.
    Varela JC; Brodsky RA
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1113-24. PubMed ID: 24168416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement and kidney disease.
    Cook HT
    Curr Opin Nephrol Hypertens; 2013 May; 22(3):295-301. PubMed ID: 23508058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation.
    Holers VM; Rohrer B; Tomlinson S
    Adv Exp Med Biol; 2013; 735():137-54. PubMed ID: 23402024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future pharmacologic complement inhibitors.
    Risitano AM
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):561-82. PubMed ID: 26043392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the complement cascade: novel treatments coming down the pike.
    Thurman JM; Le Quintrec M
    Kidney Int; 2016 Oct; 90(4):746-52. PubMed ID: 27325183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of complement in physiology and pathology].
    Klaska I; Nowak JZ
    Postepy Hig Med Dosw (Online); 2007; 61():167-77. PubMed ID: 17410057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic complement inhibition – from experimental to clinical medicine.
    Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE
    Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of complement in C3 glomerulopathy.
    Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R
    Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A computational model for the evaluation of complement system regulation under homeostasis, disease, and drug intervention.
    Zewde N; Morikis D
    PLoS One; 2018; 13(6):e0198644. PubMed ID: 29874282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
    Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dense deposit disease: new insights.
    Walker PD
    Curr Opin Nephrol Hypertens; 2007 May; 16(3):204-12. PubMed ID: 17420663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement-Mediated Microglial Phagocytosis and Pathological Changes in the Development and Degeneration of the Visual System.
    Borucki DM; Toutonji A; Couch C; Mallah K; Rohrer B; Tomlinson S
    Front Immunol; 2020; 11():566892. PubMed ID: 33072106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
    Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
    Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.